FY2026 EPS Estimates for NeuroPace Lifted by HC Wainwright

NeuroPace, Inc. (NASDAQ:NPCE) – Equities researchers at HC Wainwright upped their FY2026 earnings per share estimates for shares of NeuroPace in a research note issued to investors on Friday, May 15th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.69) per share for the year, up from their previous estimate of ($0.72). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($0.44) per share.

Several other brokerages have also recently commented on NPCE. Wall Street Zen cut NeuroPace from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Cantor Fitzgerald raised NeuroPace to a “strong-buy” rating in a research report on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a research report on Friday, March 27th. Finally, Wells Fargo & Company raised NeuroPace to a “strong-buy” rating in a research report on Wednesday, March 18th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, NeuroPace has an average rating of “Moderate Buy” and an average price target of $18.83.

NeuroPace Stock Performance

Shares of NASDAQ NPCE opened at $16.28 on Friday. The stock has a 50 day moving average price of $15.28 and a 200 day moving average price of $15.27. NeuroPace has a 52 week low of $7.56 and a 52 week high of $19.60. The company has a debt-to-equity ratio of 4.08, a quick ratio of 4.35 and a current ratio of 5.38. The stock has a market capitalization of $554.99 million, a PE ratio of -25.05 and a beta of 1.92.

NeuroPace (NASDAQ:NPCE) last released its earnings results on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.06. The firm had revenue of $22.00 million for the quarter, compared to analysts’ expectations of $21.65 million. NeuroPace had a negative return on equity of 108.20% and a negative net margin of 21.67%.

Institutional Trading of NeuroPace

A number of hedge funds have recently made changes to their positions in NPCE. First Light Asset Management LLC lifted its position in shares of NeuroPace by 82.3% in the first quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock valued at $32,349,000 after buying an additional 1,110,484 shares during the last quarter. Kotler Kevin acquired a new stake in shares of NeuroPace in the fourth quarter valued at approximately $9,750,000. Walleye Capital LLC lifted its position in shares of NeuroPace by 344.6% in the fourth quarter. Walleye Capital LLC now owns 228,847 shares of the company’s stock valued at $3,533,000 after buying an additional 177,375 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of NeuroPace by 44.6% in the second quarter. Geode Capital Management LLC now owns 485,162 shares of the company’s stock valued at $5,406,000 after buying an additional 149,595 shares during the last quarter. Finally, Armistice Capital LLC lifted its position in shares of NeuroPace by 12.6% in the third quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock valued at $13,382,000 after buying an additional 145,665 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.